Agomab Finalizes Phase 2b Study Design for Ontunisertib in Fibrostenosing Crohn's Disease, FDA Aligned

summarizeSummary

Agomab Therapeutics announced the final design of its Phase 2b NOV-ERA study for ontunisertib in Fibrostenosing Crohn's Disease, with regulatory alignment from the FDA on key elements including a novel primary endpoint.

check_boxKey Events

• Phase 2b Study Design Finalized

  Agomab announced the final design of its NOV-ERA Phase 2b study for ontunisertib in Fibrostenosing Crohn's Disease (FSCD), targeting up to 320 adult patients globally.

• FDA Alignment on Novel Endpoint

  The company achieved regulatory alignment with the U.S. FDA on the study design, including a novel primary efficacy endpoint of endoscopic passability at Week 24, de-risking the trial path.

• Study Initiation Imminent

  The study protocol has received central IRB approval in the U.S. and approval by Health Canada, with first participants expected to be dosed in the second half of 2026.

• Addressing Unmet Medical Need

  Ontunisertib, which has U.S. FDA Fast Track Designation, aims to treat FSCD, a condition affecting approximately 46% of Crohn's disease patients with no approved pharmacological therapies.

auto_awesomeAnalysis

This filing details a significant step forward in Agomab's clinical pipeline, confirming the design and regulatory alignment for a crucial Phase 2b study of ontunisertib. The FDA's agreement on a novel primary endpoint for Fibrostenosing Crohn's Disease (FSCD), an area with no approved pharmacological therapies, de-risks the trial and provides a clear path for development. The planned initiation of patient dosing in the second half of 2026 marks a key milestone for the company, potentially bringing a new treatment option to patients with high unmet medical need.